Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: Application to (R)-dimethindene occupancy of central histamine H1 receptors

Journal of Receptors and Signal Transduction

Volumn 29, Issue 2, 2009, Pages 84-93

  Malany, Siobhan ^a   Hernandez, Lisa M ^a   Smith, William F ^a   Crowe, Paul D ^a   Hoare, Sam R J ^a  

^a Divisions of Emerging New Technologies and Neuroscience   (United States)

Author keywords

Competition kinetics; Histimine receptor; Radioligand binding; Rat cortex; Receptor occupancy

Indexed keywords

DIMETINDENE; DOXEPIN; HISTAMINE H1 RECEPTOR; TRITIUM; DRUG RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN CORTEX; BRAIN HOMOGENATE; BRAIN TISSUE; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG RECEPTOR BINDING; DRUG TISSUE LEVEL; EX VIVO STUDY; IN VITRO STUDY; MALE; NONHUMAN; RADIOASSAY; RAT; RECEPTOR OCCUPANCY; REFERENCE VALUE; ROOM TEMPERATURE; SIMULATION; ANIMAL; BINDING COMPETITION; CHEMISTRY; DRUG EFFECT; KINETICS; METABOLISM;

RATTUS;

ANIMALS; BINDING, COMPETITIVE; CEREBRAL CORTEX; DIMETHINDENE; DOXEPIN; HISTAMINE H1 ANTAGONISTS; KINETICS; MALE; RADIOLIGAND ASSAY; RATS; RECEPTORS, DRUG; RECEPTORS, HISTAMINE H1;

EID: 68949170699     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890902721339     Document Type: Article

References (18)

1. Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol (1984), 25, 1-9
2. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov (2006), 5, 730-739
3. Vauquelin G, Van Liefde I, Vanderheyden P. Models and methods for studying insurmountable antagonism. Trends Pharmacol Sci (2002), 23, 514-518
4. Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci (2006), 27, 356-359
5. Schreiber G, Henis YI, Sokolovsky M. Analysis of ligand binding to receptors by competition kinetics: Application to muscarinic antagonists in rat brain cortex. J Biol Chem (1985), 260, 8789-8794 (Pubitemid 16239681)
6. Colquhoun D. The rate of equilibration in a competitive n drug system and the auto-inhibitory equations of enzyme kinetics: some properties of simple models for passive sensitization. Proc R Soc Lond B Biol Sci (1968), 170, 135-154
7. Dowling MR, Charlton S J. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol (2006), 148, 927-937
8. Sullivan SK, Hoare SR, Fleck BA, Zhu YF, Heise CE, Struthers RS, Crowe PD. Kinetics of nonpeptide antagonist binding to the human gonadotropin- releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism. Biochem Pharmacol (2006), 72, 838-849
9. Gillard M, Chatelain P. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol (2006), 530, 205-214
10. Vanderheyden PM, Fierens FL, De Backer J, Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors. Biochem Pharmacol (2000), 59, 927-935
11. Bohme TM, Keim C, Kreutzmann K, Linder M, Dingermann T, Dannhardt G, Mutschler E, Lambrecht G. Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists. J Med Chem (2003), 46, 856-867
12. Tran VT, Lebovitz R, Toll L, Snyder SH. [3H]doxepin interactions with histamine H1- receptors and other sites in guinea pig and rat brain homogenates. Eur J Pharmacol, (1981), 70, 501-509
13. Kanba S, Richelson E. Histamine H1 receptors in human brain labelled with [3H]doxepin. Brain Res (1984), 304, 1-7
14. Towart R, Sautel M, Moret E, Costa E, Theraulaz M, Weitsch AF. Investigation of the antihistaminic action of dimethindene maleate (Fenistil) and its optical isomers. Agents Actions Suppl (1991), 33, 403-408
15. Nicholson AN, Pascoe PA, Turner C, Ganellin CR, Greengrass PM, Casy AF, Mercer AD. Sedation and histamine H1-receptor antagonism: Studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol (1991), 104, 270-276
16. Passalacqua G, Canonica GW. A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. Clin Ther (2005), 27, 79-992
17. Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West RE Jr, Williams SM, Greenfeder S, Billah M, Kreutner W, Egan RE. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol (2002), 449, 229-237
18. Heise CE, Sullivan SK, Crowe PD. Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen (2007), 12, 235-239